🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  2. AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  3. AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  4. AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

    Amgen

    KRAS Altered Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  5. AMT-116

    Multitude Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  6. AMT-676

    Multitude Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  7. APR-1051

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  8. ARQ 197

    KYOWA KIRIN AUSTRALIA PTY LTD

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  9. ASTX660

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  10. ATI-2231

    Aclaris Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  11. AZD2014 3 on/4 off & weekly paclitaxel

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  12. AZD9150

    IONIS PHARMACEUTICALS INC

    Advanced Adult Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  13. Adoptive TIL therapy in combination with chemoimmunotherapy in advanced NSCLC patients

    Disc Medicine

    Respiratory tract diseases

    phase 1 other active

    1 trial

  14. Alisertib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    7 trials

  15. An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

    IDEAYA Biosciences

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  16. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

  17. An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Solid tumors and ovarian cancer

    phase 1 other active

    1 trial

  18. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  19. An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

    BioNTech SE

    Metastatic melanoma

    phase 1 other active

    1 trial

  20. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  21. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  22. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  23. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  24. Atovaquone Oral Suspension

    United Therapeutics Europe Ltd

    Locally Advanced Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources